Lipocine (LPCN) Revenue (2018 - 2025)

Lipocine's (LPCN) quarterly Revenue came in at $114574.0 in Q3 2025, down 81.6% on a QoQ basis from $622849.0 in Q2 2025.

Lipocine (LPCN) Revenue (2018 - 2025) Analysis & Trends

Lipocine (LPCN) has 7 years of Revenue data on file, last reported at $114574.0 in Q3 2025.

Quarterly Revenue changed N/A year-over-year to $114574.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.3 million (down 42.29% YoY) and the FY2024 annual result came in at $11.2 million, up 292.8% from the prior year.
Revenue retreated to $114574.0 in Q3 2025, from $622849.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $16.1 million in Q4 2021 to a low of -$216188.0 in Q4 2023.
A 5-year average of $2.6 million and a median of $307287.0 in 2022 frame the typical range for Revenue.
Annual changes were most pronounced in 2024 — Revenue surged 13751.93% — and 2025, when it plunged 98.77%.
Tracing LPCN's Revenue over 5 years: stood at $16.1 million in 2021, then plunged by 96.89% to $500000.0 in 2022, then sank by 143.24% to -$216188.0 in 2023, then surged by 1714.99% to $3.5 million in 2024, then slumped by 96.72% to $114574.0 in 2025.
The last three Revenue figures came in at $114574.0 (Q3 2025), $622849.0 (Q2 2025), and $93864.0 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Lipocine	11.34 Mn	-12.57 Mn	-	-

Download Data